GlobeNewswire

HODL RALLY Announces Updated, Networking-Centric Itinerary for 8-Day, Crypto-Inspired European Supercar Rally

Del

LONDON, June 12, 2019 (GLOBE NEWSWIRE) -- HODL RALLY, the world’s first cryptocurrency-inspired supercar rally, today announces an updated itinerary for this exciting eight-day event, which will rev its way across Europe June 30-July 7 to educate, inspire and raise awareness of the importance of blockchain technologies.

To make the lineup of events even more unique and networking-focused for the upcoming eight-day rally, organizers have elected to transcend the typical conference format characterized by combining well-known speakers and a tradeshow floor. Day 6 at the W Hotel will now feature a unique networking format that better matches the HODL RALLY’s overall spirit as opposed to following the model of most other crypto gatherings.

The Public is Invited to Attend the Kick-Off in London on the 30th at the High Wycombe Country Club

“The aim of HODL RALLY is to promote blockchain technologies in a fun and exciting environment, fusing the natural synergy between supercars and cryptocurrencies,” said HODL RALLY founder and CEO Virtue Nightingale. “This event is like nothing the blockchain world has ever seen before, so we decided every component of the rally should be as unique as the concept behind it and as transformative as the technology it promotes. For that reason, we have chosen to revise the HODL RALLY itinerary of events, and in place of the previously scheduled Barcelona Blockchain Summit we will instead host high-end blockchain networking events on July 5 at the W Hotel as part of our HODL RALLY lineup in Barcelona.”

Covering 1,800 miles, eight cities and five countries, the HODL RALLY will showcase 100 participating cars, and accompanying events will include six parties, four club takeovers, a fashion show, a poker tournament and a charity gala as the rally blazes its way through Europe.

The updated HODL RALLY itinerary is as follows:

  • June 29 – LONDON MADDOX TAKEOVER
  • June 30 – DAY 1 OF HODL RALLY – LONDON TO PARIS – PARIS CLUB TAKEOVER
  • July 1 – DAY 2 OF HODL RALLY – PARIS TO GENEVA – CRYPTO COMMUNITY MEETUP
  • July 2 – DAY 3 OF HODL RALLY – GENEVA TO MONACO – NIKKI BEACH TAKEOVER AND POKER NIGHT
  • July 3 – DAY 4 OF HODL RALLY – MONACO TO BARCELONA – SOUTH OF FRANCE COASTAL RUN
  • July 4 – DAY 5 OF HODL RALLY – 4TH OF JULY CELEBRATIONS AT W HOTEL
  • July 5 – DAY 6 OF HODL RALLY – BARCELONA BLOCKCHAIN NETWORKING EVENT BROUGHT TO YOU BY WCC EVOLV
  • July 6 – DAY 7 OF HODL RALLY – BARCELONA TO VALENCIA – CITY TOUR AND BULLFIGHTING
  • July 7 – DAY 8 OF HODL RALLY – OFFICIAL CLOSING PARTY & FASHION SHOW AT OCEAN BEACH CLUB
  • July 8 – DAY-AFTER EVENTS – HODL RALLY TAKEOVER OF KM5 IBIZA

To view full details planned for each day, visit https://hodlrally.com/  

“This incredible, unforgettable rally will be the first event of its kind and a not-to-be-missed experience,” said Nightingale. “We believe the entire world will sit up and take notice as we carry the cause of blockchain technologies across Europe in this unique and exciting way.”

About HODL RALLY

HODL RALLY is the world’s first blockchain inspired supercar rally experience. The eight-day event combines blockchain conferences with parties, dinners, fashion shows, yacht parties, club takeovers and lots of supercars. Driving across Europe, the tour will hit eight cities in eight days and will wrap up with a VIP superyacht party in Ibiza. For more details, visit  https://HODLRALLY.com/ .

Clarity PR
Maria Jung 
Maria@Clarity.pr

CryptoCurrencyWire (CCW) Contact:
New York, New York
www.CryptoCurrencyWire.com
212.418.1217 
Editor@CryptoCurrencyWire.com

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad

Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CESTPressemelding

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi